Project Grant R01DA067003
Award Date 8/15/26
Completion Date 6/30/31
Dollars Obligated $480K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- The National Institute on Drug Abuse awarded the University of California, San Diego $138,522 under the Drug Use and Addiction Research Programs (CFDA 93.279) on January 21, 2026. The award funds research evaluating the multiscale effects of fentanyl-induced dependence and abstinence within the mouse basolateral amygdala. The research employs virally-mediated strategies, nuclear labeling, and single-nucleus RNA sequencing to assess how fentanyl dependence and abstinence differentially affect...
- The National Institutes of Health Office of the Director awarded the University of Miami a project grant of $460,500 on August 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate microbiome-mediated persistent neuroimmune injury following single fentanyl exposure. The research examines how ultra-potent synthetic opioids such as fentanyl induce delayed biological injury in survivors of sub-lethal exposure, with focus on mechanisms underlying impaired cognition...
- The National Institute on Drug Abuse awarded the University of California, San Diego $1,387,755 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate mitochondrial oxidative phosphorylation dysregulation in HIV-associated neurocognitive disorder and opioid use disorder, with NAD+ treatment as a potential therapeutic strategy. The research establishes a three-dimensional human assembloid model composed of iPSC-derived neurons, astrocytes, microglia, and...
- The National Institute on Drug Abuse awarded the Regents of the University of Minnesota $673,724 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to study how opioid exposure modifies nucleus accumbens microcircuits and to develop strategies to reverse or prevent maladaptive opioid-evoked neural plasticity. The research focuses on low-threshold spiking interneurons (LTSIs) in the nucleus accumbens, which are gatekeepers of nucleus accumbens output and regulate...
- The National Institute on Drug Abuse awarded Emory University $1,095,500 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate fentanyl's impact on HIV/HBV co-infection dynamics and identify targetable metabolic pathways for therapeutic intervention. The project, titled "The Metabolic Crossroads: Decoding Fentanyl's Impact on HIV/HBV Co-Infection for Targeted Interventions," will characterize how fentanyl exposure alters viral replication...
- The National Institute on Drug Abuse awarded the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center division, $503,486 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 15, 2026. The award funds research investigating fetal fentanyl syndrome, a developmental disorder identified in 2023 in newborns exposed in utero to non-prescription fentanyl. The research examines how fentanyl inhibits post-lanosterol cholesterol...
- The National Institute on Drug Abuse awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $618,725 on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate fentanyl overdose-induced anhedonia and relapse risk. The research examines whether fentanyl overdose intensifies addiction cycles through alterations in reward processing. The project tests three specific aims: whether fentanyl overdose leads to development or...
- The National Institute on Drug Abuse awarded The Trustees of The University of Pennsylvania $708,040 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic research on distinct amygdalar neural circuits involved in pain and opioid dependence. The award funds investigation of how chronic opioid exposure alters specific brain circuits that mediate pain and threat responses, using a mouse model of fentanyl dependence compatible with postoperative pain....
- The National Institute on Drug Abuse awarded the University of Texas at Austin $490,179 under the Drug Use and Addiction Research Programs (CFDA 93.279) on May 15, 2026, to investigate the neurobiological mechanisms mediating fentanyl-induced elevations in risk taking in rats. The project uses a rat model of decision making incorporating both reward and risk of punishment to identify neural mechanisms responsible for fentanyl-induced increases in risk taking after prolonged abstinence. The...
- The National Institutes of Health Office of the Director awarded Beth Israel Deaconess Medical Center $508,734 on August 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the neural mechanisms underlying fentanyl-xylazine overdose lethality and identify therapeutic reversal strategies. The award funds research into how fentanyl and xylazine—a veterinary sedative increasingly found as an adulterant in illicit opioid supplies—synergistically inhibit lateral...